Sentigen Holding Corp. Stockholders Approve Merger with Invitrogen Corporation

  
    
  
  
    
      Sentigen Holding Corp. (Nasdaq:SGHL) today announced that at the special 
      meeting of stockholders held today, Sentigen stockholders approved the 
      adoption of the agreement and plan of merger with Invitrogen Corporation 
      (Nasdaq:IVGN), a global leader in life sciences. The transaction was 
      approved by more than 50% of the shares outstanding. Based on 
      discussions to date with Invitrogen, and contingent upon the 
      satisfaction of specified closing conditions, Sentigen believes that the 
      merger with Invitrogen will be completed within the next several weeks.
    
    
      As previously announced, on August 31, 2006, Sentigen and Invitrogen 
      entered into a definitive merger agreement under which Invitrogen will 
      acquire Sentigen in a cash transaction at a price of $3.37 per share for 
      all shares currently issued and outstanding.
    
    
      Prior to the merger, it is expected that Sentigen will distribute the 
      shares of SentiSearch, Inc., a newly-formed corporation, in a taxable 
      transaction, pro rata to the then existing stockholders of Sentigen. 
      SentiSearch, Inc. is expected to be a publicly traded company, initially 
      holding certain olfaction intellectual property previously owned by 
      Sentigen.
    
    
      Additional Information about the proposed merger and where you can 
      find it
    
    
      In connection with the proposed merger, Sentigen has filed a proxy 
      statement and other relevant materials with the Securities and Exchange 
      Commission (“SEC”). 
      The proxy statement and other relevant materials, and any other 
      documents filed by Sentigen with the SEC, may be obtained free of charge 
      at the SEC’s web site at www.sec.gov.
    
    
      About Sentigen Holding Corp.
    
    
      Sentigen Holding Corp. conducts business through two wholly-owned 
      operating subsidiaries: Sentigen Biosciences, Inc. (“Sentigen 
      Biosciences”) and Cell & Molecular 
      Technologies, Inc. (“CMT”). 
      CMT provides contract research and development services to companies 
      engaged in the drug discovery process in the following areas: molecular 
      and cell biology, gene expression and protein biochemistry, 
      bio-processing, high throughput screening support services, mouse 
      genetics, and cell-based GPCR selectivity profiling. Sentigen 
      Biosciences has been primarily engaged in the development and 
      commercialization of novel bioassay systems that elucidate the 
      underlying biology of protein-protein interactions. Sentigen Biosciences 
      has initially targeted its Tango™ Assay System 
      to address the functionalization of G protein-coupled receptors (GPCRs) 
      for pharmaceutical drug discovery and development. For more information 
      on our companies, please visit their respective websites: www.cmt-inc.net 
      and www.sentigen.com.
    
    
      Safe Harbor Statement
    
    
      This news release includes forward-looking statements that involve risks 
      and uncertainties. Although Sentigen believes such statements are 
      reasonable, it can make no assurance that such statements will prove to 
      be correct. Such statements are subject to certain factors that may 
      cause results to differ materially from the forward-looking statements. 
      Such factors include the risk factors discussed in Sentigen's filings 
      with the Securities and Exchange Commission, including its most recent 
      Annual Report on Form 10-K and the merger proxy dated October 13, 2006, 
      copies of which may be obtained from Sentigen without charge. Sentigen 
      undertakes no obligation to publicly release results of any of these 
      forward-looking statements to reflect events or circumstances after the 
      date hereof or to reflect the occurrence of unexpected results.
    
  
Sentigen Holding Corp. (Nasdaq:SGHL) today announced that at the
special meeting of stockholders held today, Sentigen stockholders
approved the adoption of the agreement and plan of merger with
Invitrogen Corporation (Nasdaq:IVGN), a global leader in life
sciences. The transaction was approved by more than 50% of the shares
outstanding. Based on discussions to date with Invitrogen, and
contingent upon the satisfaction of specified closing conditions,
Sentigen believes that the merger with Invitrogen will be completed
within the next several weeks.

   As previously announced, on August 31, 2006, Sentigen and
Invitrogen entered into a definitive merger agreement under which
Invitrogen will acquire Sentigen in a cash transaction at a price of
$3.37 per share for all shares currently issued and outstanding.

   Prior to the merger, it is expected that Sentigen will distribute
the shares of SentiSearch, Inc., a newly-formed corporation, in a
taxable transaction, pro rata to the then existing stockholders of
Sentigen. SentiSearch, Inc. is expected to be a publicly traded
company, initially holding certain olfaction intellectual property
previously owned by Sentigen.

   Additional Information about the proposed merger and where you can
find it

   In connection with the proposed merger, Sentigen has filed a proxy
statement and other relevant materials with the Securities and
Exchange Commission ("SEC"). The proxy statement and other relevant
materials, and any other documents filed by Sentigen with the SEC, may
be obtained free of charge at the SEC's web site at www.sec.gov.

   About Sentigen Holding Corp.

   Sentigen Holding Corp. conducts business through two wholly-owned
operating subsidiaries: Sentigen Biosciences, Inc. ("Sentigen
Biosciences") and Cell & Molecular Technologies, Inc. ("CMT"). CMT
provides contract research and development services to companies
engaged in the drug discovery process in the following areas:
molecular and cell biology, gene expression and protein biochemistry,
bio-processing, high throughput screening support services, mouse
genetics, and cell-based GPCR selectivity profiling. Sentigen
Biosciences has been primarily engaged in the development and
commercialization of novel bioassay systems that elucidate the
underlying biology of protein-protein interactions. Sentigen
Biosciences has initially targeted its Tango(TM) Assay System to
address the functionalization of G protein-coupled receptors (GPCRs)
for pharmaceutical drug discovery and development. For more
information on our companies, please visit their respective websites:
www.cmt-inc.net and www.sentigen.com.

   Safe Harbor Statement

   This news release includes forward-looking statements that involve
risks and uncertainties. Although Sentigen believes such statements
are reasonable, it can make no assurance that such statements will
prove to be correct. Such statements are subject to certain factors
that may cause results to differ materially from the forward-looking
statements. Such factors include the risk factors discussed in
Sentigen's filings with the Securities and Exchange Commission,
including its most recent Annual Report on Form 10-K and the merger
proxy dated October 13, 2006, copies of which may be obtained from
Sentigen without charge. Sentigen undertakes no obligation to publicly
release results of any of these forward-looking statements to reflect
events or circumstances after the date hereof or to reflect the
occurrence of unexpected results.